Day: December 13, 2022

Cornerstone Files Management Information Circular for Proposed Arrangement with SolGold

Written by Customer Service on December 13, 2022. Posted in Mergers And Acquisitions.

OTTAWA, Dec. 13, 2022 (GLOBE NEWSWIRE) — Cornerstone Capital Resources Inc. (“Cornerstone”) (TSXV:CGP; OTC:CTNXF; FWB:GWN1) is pleased to announce that it has filed and commenced mailing its management information circular (the “Circular”) and related materials in connection with the special meeting (the “Meeting”) of Cornerstone shareholders (the “Shareholders”) to be held in virtual-only format via live webcast at 9:00 a.m. (Eastern Time) on January 9, 2023 to approve the previously-announced plan of arrangement (the “Arrangement”) with SolGold plc (LSE:SOLG; TSX:SOLG) (“SolGold”), all as more particularly described in the Circular. The Circular provides important information regarding the Arrangement and related matters, including the background to the Arrangement, the reasons for unanimous recommendation of the board of directors...

Vision Marine’s E-Motion™ Electric Propulsion System to be Rolled Out Across Groupe Beneteau Brand Portfolio Per Strategic Master Supplier Agreement

Written by Customer Service on December 13, 2022. Posted in Public Companies.

MONTREAL, Dec. 13, 2022 (GLOBE NEWSWIRE) — Vision Marine Technologies, Inc. (NASDAQ: VMAR) (“Vision Marine” or the “Company”), the global leader and innovator within the performance electric recreational boating industry, is pleased to announce that Vision Marine has entered into a formal Supplier Agreement with Groupe Beneteau (BEN-Euronext) (“Beneteau”). This Agreement marries the world’s first purpose built, fully electric outboard motor and powertrain system, the E-Motion™ 180E, with the excellent legacy reputation and technical prowess of Groupe Beneteau. The Four Winns H2e was designed and marketed as the seminal and groundbreaking electric boating experience for the consumer. This agreement further solidifies the relationship between Vision Marine and Beneteau, which was previously announced on July 19, 2022. The...

Jushi Holdings Inc. Unveils Cannabis Brand Portfolio in California

Written by Customer Service on December 13, 2022. Posted in Public Companies.

Jushi Holdings Inc. Announces Launch of its Comprehensive Product Suite in California Jushi Holdings Inc., a vertically integrated, multi-state cannabis operator, announced the launch of its comprehensive product suite in California, exclusively available at the Company’s Beyond Hello™ retail locations in the Golden State. Bringing a new selection of high-quality brands and proprietary products, the launch features three brands crafted to meet cannabis consumers’ preferences and price points: Sèchè™ Pre-Roll Singles, Tasteology™ Fruit Chews and The Lab Vapes.Sèchè Pre-Roll Singles, Tasteology Fruit Chews and The Lab Vapes Bring California Consumers High-Quality, Value-Added Cannabis Products BOCA RATON, Fla., Dec. 13, 2022 (GLOBE NEWSWIRE) — Jushi Holdings Inc. (“Jushi” or the “Company”) (CSE: JUSH) (OTCMKTS:...

Draganfly’s Commander 3 XL Wins Best Enterprise Drone at the Droning Awards

Written by Customer Service on December 13, 2022. Posted in Public Companies.

Draganfly’s Commander 3 XL Drone is a high-endurance, weather-resistant, multirotor UAV, designed for easy assembly and rapid deployment Los Angeles, CA., Dec. 13, 2022 (GLOBE NEWSWIRE) — Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, is honored to announce its Commander 3 XL Drone has been voted Best Enterprise Drone at The Droning Company’s Annual Droning Awards. The Droning Company was named The World’s # 1 Resource for the Drone Community. To honor and celebrate this community, the Droning Company created The Droning Awards to recognize and celebrate outstanding drone innovations for 2022 and allow drone pilots and enthusiasts to vote in a series of categories. The Commander 3 XL Drone is one of three new products...

Midland Begins an Important Drilling Program Totalling 10,000 Metres on Its Gold and Ni-Cu Projects in Abitibi

Written by Customer Service on December 13, 2022. Posted in Public Companies.

Figure 1 Geology Abitibi-ADDP Drilling ProgramMONTREAL, Dec. 13, 2022 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the beginning of a major drilling program, totalling more than 10,000 metres, on its gold and Ni-Cu projects in the Abitibi region. This aggressive drilling program will test more than 40 of the best exploration targets developed over the past few years on the Company’s projects in the Abitibi region, following historical drilling, geophysical and biogeochemical surveys. The five (5) projects targeted under the program are all located proximal to major gold-bearing structures in the Abitibi, such as the Cadillac-Larder Lake, Destor-Porcupine, Lower Detour /Bapst and Opawica-Guercheville faults. These large-scale regional structures are all important metallotects and...

Innovation Pharmaceuticals Reports New In Vivo Antifungal Data Showing Brilacidin’s Potential for Treating Fungal Keratitis

Written by Customer Service on December 13, 2022. Posted in Public Companies.

Additionally, Brilacidin to be Screened by NIH/NIAID to Further Characterize Its Broad-Spectrum Antifungal Activity WAKEFIELD, MA, Dec. 13, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provided an update on ongoing research on the broad-spectrum antifungal activity of Brilacidin, the Company’s defensin mimetic drug candidate exhibiting antimicrobial and immunomodulatory properties. Previous research conducted primarily by scientists at the University of São Paulo (USP), Brazil, showed Brilacidin can potentiate several marketed antifungals, including caspofungin, voriconazole and posaconazole. Moreover, Brilacidin exhibited potent stand-alone efficacy (MIC=2.5µM) against C. neoformans – a deadly fungus that causes an estimated...

Arbutus Completes Enrollment in its Phase 2a Clinical Trial Combining AB-729 with NA Therapy and Peginterferon alfa-2a in Patients with Chronic Hepatitis B Virus Infection

Written by Customer Service on December 13, 2022. Posted in Public Companies.

Preliminary data from lead-in phase further validates AB-729’s capacity to reduce HBsAg Initial data from IFN phase expected in the first half of 2023 WARMINSTER, Pa., Dec. 13, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced preliminary data from the AB-729 lead-in portion of its Phase 2a clinical trial combining AB-729 with nucleos(t)ide analogue (NA) therapy and Peginterferon alfa-2a (IFN). The data reinforces AB-729’s surface antigen reducing-capacity, while continuing to exhibit a generally safe and well-tolerated profile in patients with chronic Hepatitis B virus (cHBV). Given that only a few patients are in the early weeks of the IFN...

Syneos Health Extends Partnership with Medable

Written by Customer Service on December 13, 2022. Posted in Public Companies.

Continued Collaboration Will Accelerate Bringing Clinical Trials Closer to the Patient MORRISVILLE, N.C., Dec. 13, 2022 (GLOBE NEWSWIRE) — Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced it has extended its strategic partnership with Medable, the industry-leading technology platform for patient-centered clinical trials, as part of the Company’s commitment to bring clinical trials closer to the patient. Together, Syneos Health and Medable will continue to reduce site and patient burden, improve enrollment and retention and increase patient access and diversity through innovative decentralized clinical trial (DCT) solutions. Syneos Health first partnered with Medable in April 2021. Notably, over the past 18 months, Syneos Health and Medable have collaborated on more...

Amedisys Completes Home Health Joint Venture with the University of Arkansas for Medical Sciences

Written by Customer Service on December 13, 2022. Posted in Public Companies.

LITTLE ROCK, Ark. and NASHVILLE, Tenn., Dec. 13, 2022 (GLOBE NEWSWIRE) — Amedisys, Inc. (NASDAQ: AMED), a leading provider of quality home health, hospice, personal care and high-acuity care, has closed on its joint venture with the University of Arkansas for Medical Sciences (UAMS) to provide home health services in Searcy and Little Rock. This joint venture is part of the partnership between UAMS, Amedisys and Contessa, an Amedisys company, to offer patients a full spectrum of medical care in the comfort and convenience of their own homes through UAMS Health Comprehensive Care at Home. Clinical services will include Recovery Care at Home, Rehabilitation Care at Home, Palliative Care at Home, Primary Care at Home and Home Health. Home health services include skilled nursing care; physical, occupational and speech therapy; medical...

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

Written by Customer Service on December 13, 2022. Posted in Public Companies.

NEW YORK, Dec. 13, 2022 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces the initiation of INDP-D101, its first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors. The USC Norris Cancer Center in Los Angeles, California is the first activated clinical trial site that has been opened for patient enrollment, and patient screening is expected soon. The study’s objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to assess Decoy20 pharmacokinetics (PK),...

M	T	W	T	F	S	S
			1	2	3	4
5	6	7	8	9	10	11
12	13	14	15	16	17	18
19	20	21	22	23	24	25
26	27	28	29	30	31

Day: December 13, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals